Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
Dr. Robert Palmason discusses the results of a study investigating if SARS-CoV-2 vaccination impact the risk of progression from MGUS to multiple myeloma.
In patients with monoclonal gammopathy of undetermined significance (MGUS), the pre-malignant cells are antibody producing plasma cells. Stimulating humoral immunity mediated by plasma cells is an important factor in vaccine efficacy. Therefore, concerns have been raised about whether vaccine administration in patients with MGUS could trigger progression of the underlying pre-malignant clone, leading to an increase in the monoclonal-(M)-protein or even progression to full-blown malignancy. Immune stimulation has been found to be a risk factor for monoclonal gammopathies. However, immune stimulation inherent to vaccines and the subsequent antibody formation by plasma cells has, to our knowledge, not been studied in a systematic manner in MGUS. The current SARS-CoV-2 pandemic provide a unique opportunity to evaluate if SARS-CoV-2 vaccination has an impact on the risk of progression from MGUS to MM, or not. To study this we performed a prospective nationwide study based on the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study.
In this large, prospective, population-based, screening study including 1,814 individuals with MGUS who were observed before and after covid vaccinations, we found no evidence for MGUS progression after SARS-CoV-2 vaccination. The same was true when analyzed separately by sex, age, type of vaccine, and the number of doses given. Our findings indicate that SARS-CoV-2 vaccination is safe in individuals with MGUS and does not lead to progression irrespective of the number of vaccine doses administered and type of vaccine used.
Robert Palmason, MD, Elias Eythorsson, MD, PhD, Sæmundur Rögnvaldsson, MD, Sigrun Thorsteinsdottir, MD, PhD, Sara Ekberg, PhD, Michael Crowther, PhD, Elin Ruth Reed, Jon Þórir Oskarsson, MSc, Gudrun Asta Sigurdardottir, Thor Aspelund, PhD, Brynjar Vidarsson, MD, Pall Torfi Onundarson, MD, Bjarni Agnar Agnarsson, MD, Margret Sigurdardottir, MD, Ingunn Thorsteinsdottir, MD, PhD, Signy Vala Sveinsdottir, MD PhD, Isleifur Olafsson, MD, PhD, Asdis Rosa Thordardottir, Asbjorn Jonsson, MD, Olafur Skuli Indridason, MD, MHS, Gauti Gislason, Andri Olafsson, Jon Kristinn Sigurdsson, Hlif Steingrimsdottir, MD, Thorir Einarsson Long, MD, PhD, Malin Hultcrantz, MD, PhD, Brian G.M. Durie, MD, Stephen Harding, PhD, Ola Landgren, MD, Runolfur Palsson, MD, Thorvardur Jon Love, MD, PhD and Sigurdur Y Kristinsson, MD, PhD
ASH Abstract #105: https://ash.confex.com/ash/2022/webprogram/Paper157138.html
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma
Visit our website at: https://www.myeloma.org
Find us online:
Facebook: @myeloma | https://facebook.com/myeloma
Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma
Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma
Support the IMF | Donate Now! https://secure.myeloma.org/page/40697/donate/1
Nonprofits & Activism
Standard YouTube License
In most cases, captions are autogenerated by YouTube.